Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. see more

OTCQX:MRVFF - Post Discussion

View:
Post by ValueCap on Nov 05, 2019 6:49pm

Resultz

Nuvo completed the tech transfer and the Varennes facility is set up to manufacture Resultz to its distributors, which adds one layer of value.

The team apparently is still incentivized to sign a US distributor by year end.

They are hoping for a multiple in the teens of revenues. 

Resultz typically dominates a market that it’s in.

Here’s an estimate for the US lice market - 440 million by 2024.

If you include an upfront payment, licensing revenue royalties, and sales from manufacturing at Varennes, that’s a good number to the bottom line.

I get that the team is incentivized for year end and have been in talks with a potential distributor. I hope they make it happen. 

https://www.marketwatch.com/press-release/head-lice-infestation-drug-market-size-to-surge-at-43-cagr-poised-to-touch-usd-440-million-by-2024-2019-05-10
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities